Litvinova L., Skuratovskaia D., Komar A., Vulf M., Kirienkona E., and Zatolokin P
Immanuel Kant Baltic Federal University, Russia
Scientific Tracks Abstracts: J Mol Genet Med
Introduction: Visfatin has multidirectional effects-pro-inflammatory, stimulating the production of proinflammatory
cytokines, and neuro-, angioprotective properties. Adipokine has an insulin-mimetic effect
and stimulates insulin production. In this regard, the aim of the study was to study the role of visfatin in
the development of type 2 diabetes in patients with obesity.
Methodology & Theoretical Orientation: Serum glucose levels were determined using a biochemistry
analyzer. Using the method of flow fluorimetry, the content of visfatin, insulin and leptin in the blood
plasma was determined using commercial test systems; gene expression level - by PCR.
Findings: In the group of obese patients with type 2 diabetes, the content of leptin, insulin and glucose
in the blood plasma was higher, which was the case for patients without type 2 diabetes and control (p
<0.05). The level of visfatin in blood plasma was higher than 802.10 (101.0 - 1145.12) pg / ml than in
patients with obesity without type 2 diabetes 371.81 (40.83 - 513.58) pg / ml and below the control values
(p <0.05). In the group of obese patients with type 2 diabetes, the level of visfatin positively correlated
with the level of leptin (r = 0.513) and negatively with the level of insulin (r = -0.435) (p <0.05). However,
in patients without type 2 diabetes, the level of visfatin had positive correlations with the content of
insulin (r = 0.812) and leptin (r = 0.767) in blood plasma (p <0.05). The expression level of the NAMPT
gene (visfatin) was increased in all obese patients with type 2 diabetes in all fat depots, compared with
obese patients without it. In obese patients with type 2 diabetes, the level of NAMPT gene expression
in subcutaneous adipose tissue was 15 times higher than the control group (p <0.05), while in patients
without type 2 diabetes it did not differ from the control, which may indicate the formation of adipokine
plasma levels, mainly due to its production of subcutaneous fat depot in patients with type 2 diabetes. The
level of NAMPT gene expression in the greater omentum positively correlated with the level of Visfatin in
blood plasma in the group of obese patients with type 2 diabetes (r = 0.5 p <0.05). The level of NAMPT
gene expression in the mesentery of the small intestine negatively correlated with BMI in the group of
obese patients with type 2 diabetes (r = 0.4 p <0.05).
Conclusion & Significance: Thus, visfatin can have different effects on the development of type 2 diabetes
in obese patients, mediated by tissue-specific features of its secretion, as indicated by (1) the revealed formation of plasma levels of adipokine due to subcutaneous fat depot in patients with type 2 diabetes;
(2) the detected protective effects of visfatin in patients without type 2 diabetes, due to the established
positive relationship between the level of visfatin and plasma insulin production in this category of
patients.
Litvinova Larisa has completed her MD and currently she is working as Head of Laboratory, Immunology and Cell Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation. She has published more than 180 papers in reputed journals.
E-mail: larisalitvinova@yandex.ru
Molecular and Genetic Medicine received 3652 citations as per Google Scholar report
